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Metastasis is the leading cause of cancer-associated
death but has been difficult to study because it
involvesaseriesof rare, stochasticevents. Tocapture
these events, we developed a sensitivemethod to tag
and track pancreatic epithelial cells in amousemodel
of pancreatic cancer. Tagged cells invaded and
entered the bloodstream unexpectedly early, before
frank malignancy could be detected by rigorous
histologic analysis; this behavior was widely associ-
atedwithepithelial-to-mesenchymal transition (EMT).
Circulating pancreatic cells maintained a mesen-
chymal phenotype, exhibited stem cell properties,
and seeded the liver. EMT and invasiveness were
most abundant at inflammatory foci, and induction
of pancreatitis increased the number of circulating
pancreatic cells. Conversely, treatment with the im-
munosuppressive agent dexamethasone abolished
dissemination. These results provide insight into the
earliest events of cellular invasion in situ and suggest
that inflammation enhances cancer progression in
part by facilitating EMT and entry into the circulation.
INTRODUCTION
Each step in the metastatic cascade is highly inefficient. Only
a small fraction of cells from a primary tumor enter the circula-
tion, and less than 0.01% of these develop into metastases
(Gupta et al., 2005). It is thought that tumor cells pass through
several stages during which they sequentially acquire the ability
to invade through basement membrane(s), enter and exit the
bloodstream, and survive and grow in distant organs. Because
each of these events is rare, studies of the metastatic process
have relied heavily upon cells that have been cultured andmanipulated in vitro and reintroduced into recipient animals. As
a result, there remains considerable uncertainty regarding the
factors that influence each stage in vivo as well as the timing of
dissemination itself.
Clinical observations, mainly in the field of breast cancer, have
given rise to two major metastasis paradigms. The classical
model treats metastasis as the final step in a progressive
‘‘Darwinian’’ sequence, in which tumors acquire mutations that
promote invasive behavior and dissemination late in tumor
evolution (Cairns, 1975). This model has several conceptual
problems (Gupta et al., 2005; Klein, 2009) and fails to account
for two clinical observations: the appearance of metastatic
lesions years after resection of small tumors with no clinically
evident metastases at diagnosis (Pantel et al., 2008) and metas-
tases of unknown primary tumors, which account for as many as
4%–5% of all clinical metastases (Greco and Hainsworth, 2009).
An alternative model has been proposed that envisions metas-
tasis as an inherent feature of a tumor very early in its natural
history (Hellman, 1994; Klein, 2009). Although direct evidence
for this model is limited, recent studies of breast cancer are
consistent with the notion that metastatic seeding may be medi-
ated by cells that would not meet a standard definition of cancer
(Hu¨semann et al., 2008; Podsypanina et al., 2008). Furthermore,
several small studies concluded that the presence of putative
disseminated tumor cells in the bone marrow of patients with
low-grade mammary tumors or carcinoma in situ correlates
with a worse outcome (Ignatiadis et al., 2011; Sa¨nger et al.,
2011). The possibility that cellular dissemination leading to
metastasis occurs prior to the formation of an identifiable
primary tumor has significant clinical and biological implications.
One of the challenges in studying tumor cell dissemination has
been the identification of markers that distinguish cancer cells
from cells that normally reside in the bloodstream or at sites of
seeding. During malignant progression, it has been proposed
that carcinoma cells undergo an epithelial-to-mesenchymal
transition (EMT), in which they lose epithelial characteristics
and acquire invasive properties and stem cell-like featuresCell 148, 349–361, January 20, 2012 ª2012 Elsevier Inc. 349
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Figure 1. Lineage-Labeled Mouse Models of Pancreatic Cancer and Detection of EMT
(A) Schematic of the PKCY mouse model used in this study, which employs the KrasG12D (‘‘K’’), Pdx1-Cre (‘‘C’’), p53 (‘‘P’’), and RosaYFP (‘‘Y’’) alleles
(see Experimental Procedures). Cre-mediated activation of Kras and deletion of one allele of the p53 tumor suppressor are accompanied by recombination of the
YFP lineage label.
(B) Bright-field and fluorescent images of midgut organs from a CY mouse showing robust and specific fluorescence of the pancreas (outlined); some labeling is
also present in the duodenum.
(C) Time course of malignant progression in PKCY mice.
(D–F) Representative images of malignant progression. Prior to weaning, PKCY mice have histologically normal pancreata (D) but develop PanIN lesions (E) and
eventually PDAC (F).
(G–I) Images of pancreata from (D)–(F) stained with an antibody against YFP (green) and N-cadherin (N-cad, red); prior to weaning, scant N-cad staining is
seen (G).
(J and K) Fluorescent images of lineage-labeled cells derived from the pancreatic epithelium. In control (CY; Pdx-Cre; YFP) pancreata, YFP+ cells express
E-cadherin (E-cad; J) but not N-cad (K). Dotted lines indicate YFP mesenchymal cells.
350 Cell 148, 349–361, January 20, 2012 ª2012 Elsevier Inc.
(Polyak and Weinberg, 2009). Although several studies support
a physiologic role during tumor progression (Moody et al.,
2005; Trimboli et al., 2008), most studies of EMT in the context
of cancer biology have been conducted in vitro, and thus the
relevance of EMT to carcinogenesis continues to be debated
(Ledford, 2011). If EMT does play a crucial role in cancer cell
spread in vivo, then detection methods that rely on cellular
expression of epithelial markers alone are likely to provide an
incomplete picture of metastasis.
To understand the early events that accompany invasive
behavior, we developed a lineage-labeling system to detect
and isolate cells of pancreatic epithelial origin during stochastic
tumor progression. This system allowed us to determine the
kinetics of EMT and hematogenous dissemination during the
natural evolution of pancreatic ductal adenocarcinoma (PDAC)
in vivo and correlate cell phenotype with the acquisition of inva-
sive and tumor-initiating properties.
RESULTS
Enhanced Detection of EMT using Epithelial
Lineage Tracing
We used a Cre-lox-based mouse model of PDAC to study the
fate of pancreatic epithelial cells during various stages of tumor
progression (Bardeesy et al., 2006). The model relies on the
Pdx1-Cre transgenic strain (Gu et al., 2003) to generate
pancreas-specific mutations in Kras and p53, genes that are
mutated with high frequency in human pancreatic cancers (Hezel
et al., 2006). In order to track pancreatic epithelial cells during
tumor progression, we introduced a RosaYFP allele into the
mutant background, resulting in highly specific and efficient
(>95%) labeling (Figures 1A and 1B). Animals containing all four
alleles were referred to as PKCYmice. A secondmodel, in which
a single allele of p16Ink4a/Arf was deleted in place of p53 (IKCY;
Aguirre et al., 2003), was also employed and yielded similar
results (data not shown). The lineage-labeled mousemodels dis-
played similar histology as nonlabeled models, including the
development of pancreatic intraepithelial neoplasias (PanINs),
primary tumors, and metastases, with reproducible kinetics
(Figures 1C–1I). Because the Pdx1 promoter is active only in
endoderm-derived pancreatic cells (Gu et al., 2003), only the
epithelium was tagged by this method. Importantly, mesen-
chymal cells were never labeled under control conditions in
Pdx1-Cre; RosaYFP (CY) animals (Figures 1J and 1K).
Initially, we looked for cancer cells that coexpressed an
epithelial marker and a mesenchymal marker, a standard
approach used to detect cells at an ‘‘intermediate stage’’ of
EMT. In the course of these studies, we used several mesen-
chymal markers (Figure S1 available online) but focused our
analysis on Zeb1 and Fsp1 as these markers serve as indepen-
dent predictors of mortality in patients with pancreatic cancer
(Brabletz et al., 2011; Wang et al., 2007). Using this method,(L–Q) Images of sections from control (CY; L–N) or PDAC (PKCY; O–Q) pancreata c
E-cad (N and Q). Insets and arrowheads in (O)–(Q) show high-magnification view
derived (YFP+) cells that have acquired expression of the mesenchymal marker
marker E-cad (Q).
Scale bars denote 100 mm in (G)–(I) and (L)–(Q) and 10 mm in (J) and (K). See alsowe detected tumor cells in tumor-bearing mice (‘‘PDAC mice’’)
that coexpressed either Zeb1 or Fsp1 and the epithelial marker
E-cadherin (E-cad; Figure 1O), indicating that such ‘‘bipheno-
typic’’ cells exist, albeit at a low frequency (<10%).
We then used the YFP lineage label to identify PDAC cells that
had completed an EMT. Because labeling was limited to cells of
epithelial origin,wedefinedEMTashavingoccurred if a cell coex-
pressed YFP and either Zeb1 (Figure 1P) or Fsp1 (Figure S1D)
and/or lacked E-cad (Figure 1Q) expression. Using this
approach, we observed that 42% of the lineage-labeled YFP+
cells in PKCY tumors had undergone EMT (Figure 1P); higher
rates of EMT (68%of all YFP+ cells) were found in the IKCYmodel
(data not shown). EMT was not detected in lineage-labeled CY
control mice by either method (Figures 1L–1N). Thus, genetic
lineage marking is a sensitive tool for distinguishing cells of
epithelial and mesenchymal origin and for the detection of EMT.
EMT in Premalignant Lesions
EMT has been proposed to be a prerequisite for invasion and
dissemination of carcinoma cells (Hanahan and Weinberg,
2011). To determine when EMT first occurs during PanIN-to-
carcinoma progression, we analyzed 8- to 10-week-old PKCY
mice. At these time points, only precancerous PanIN lesions
were present, and there was no histological evidence of PDAC
based on extensive H&E analysis (n = 18); these animals were
referred to as ‘‘PanINmice’’ solely to reflect the histological state
of the pancreas at these time points.
EMT was identified in premalignant lesions from both models
(Figures 2B, 2C, S1B, and S1C; data not shown). 2.7% and 6.8%
of all PanIN 2 and 3 lesions, respectively, contained at least one
YFP+Zeb1+ cell, whereas EMT was never observed in PanIN 1
lesions (Figures 2A and 2E). Similar results were noted with other
mesenchymal markers, including Fsp1, Slug, Snail1, and Sip1
(Figure S1). EMT was also prevalent in areas of acinar-to-ductal
metaplasia (ADM), particularly in lesions surrounded by abun-
dant inflammatory cells (Figures 2D and S2A). We refer to these
areas as ADMIs (acinar-to-ductal metaplasia with inflammation)
and determined that 15.8% of ADMIs had evidence of EMT in 8-
to 10-week-old PKCY PanIN mice (Figure 2E).
We sorted YFP+ cells and performed qPCR to confirm that
epithelium-derived pancreatic cells activated a mesenchymal
program at the transcriptional level (Figure 2F). Transcripts for
Zeb1, Fsp1, and N-cadherin were found in YFP+ cells from
tumor-bearing PKCY animals and PanIN animals but not in
YFP+ cells from CY control mice (Figure 2G; p < 0.01). These
data indicate that EMT occurs in PanIN lesions and ADMIs prior
to tumor formation.
Pancreatic Epithelial Cells Spread before
Tumor Formation
Cells that have undergone EMT acquire an invasive phenotype
in vitro (Polyak and Weinberg, 2009). Thus, we hypothesizedostained with E-cad and Zeb1 (L andO); YFP and Zeb1 (M and P); and YFP and
s of cells that coexpress an epithelial and mesenchymal marker (O), epithelial-
Zeb1 (P), or epithelial-derived cells that have lost expression of the epithelial
Figure S1.
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Figure 2. EMT Precedes Tumor Formation
(A–D) In pancreata taken from 8- to 10-week-old PKCYmice, EMT is observed in regions of acinar-to-ductal metaplasia with inflammation (ADMI; D), PanIN 2 (B),
PanIN 3 (C), but not in PanIN 1 lesions (A). Arrows show individual YFP+ cells (green) that also express Zeb1 (red).
(E) Quantification of observations from (A)–(D), showing the percentage of each type of lesion having at least one cell that has undergone EMT; numbers reflect at
least ten medium-powered fields from each of five PanIN mice.
(F) Strategy for isolating YFP+ epithelially derived cells from the pancreas; the purity of the YFP+ population was confirmed by a repeat FACS analysis.
(G) Transcriptional analysis of sorted YFP+ pancreas cells from lineage-labeled CY control (n = 4), PanIN (n = 6), and PDAC (n = 5) pancreata.
Bar graph data are presented as mean ± standard deviation (SD) in this and subsequent figures. *p < 0.01; **p < 0.001 by two-tailed Student’s t test in this and
subsequent figures, unless otherwise noted. Scale bars, 20 mm. See also Figure S2.that cells that undergo EMT in PanIN mice might also have inva-
sive properties. Consistent with this notion, we identified indi-
vidual YFP+ cells that had traversed the basement membrane
and dissociated from any discernible pancreatic epithelial struc-
ture (a process we refer to as ‘‘delamination’’) in mice bearing
PanIN 2 and PanIN 3 lesions (Figures 3A and S2A). Most of these
cells expressed Zeb1 (Figure 3A, i–iii) and had acquired a fibro-
blast-like morphology, making them indistinguishable from
surrounding stromal cells by conventional histology (Figures
3A, 3B, and S2); a fraction of the delaminated YFP+ cells also352 Cell 148, 349–361, January 20, 2012 ª2012 Elsevier Inc.expressed Fsp1 (Figure S2A, insets). To rule out the possibility
that the Pdx1 promoter might be ectopically activated in mesen-
chymal cells during premalignant progression, we performed
lineage tracing in Mist1CreERT2 mice whose acinar cells had
been labeled by tamoxifen pulse. In the setting of experimental
pancreatitis (as described in greater detail below), Mist1CreERT2;
KrasG12D; RosaYFP pancreata contained fibroblast-like YFP+
cells that lacked E-cad expression (Figure S2B). Because
Mist1CreERT2 mediates labeling solely at the time of tamoxifen
administration (Habbeet al., 2008), this experimentdemonstrates
unambiguously that the labeledmesenchymal cells were derived
from pancreatic acinar cells in vivo.
To extend these studies, we performed immunostaining for
the Pdx1 transcription factor. Pdx1 is normally expressed at
high levels during pancreatic development and in adult b cells,
and it is commonly ‘‘reactivated’’ in human PanIN lesions and
in PDAC (Park et al., 2011). Pdx1 was widely expressed in PanIN
lesions and in a subset of YFP+ cells that had delaminated in
PanIN mice (Figure S3A). Consistent with these data, sections
of human pancreas that contained PanIN lesions (but no tumor)
exhibited scattered Pdx1+ cells that were separated from any
defined epithelial structure (Figures S3B–S3D). Thus, human
pancreatic cells may delaminate from PanIN lesions as they do
in the mouse model.
Because lineage tracing demonstrated that pancreatic cells
can cross the basement membrane before invasive behavior is
detectable by standard histology, we asked whether these cells
could also enter the bloodstream prior to tumor formation. In
tumor-bearing PDAC mice, YFP+ circulating pancreatic cells
(CPCs) were readily detected in the blood by flow cytometry
(Figure 3E). Surprisingly, CPCs were also abundant in the blood-
stream of 8- to 10-week-old PKCY PanIN mice (Figures 3C–3G).
Sorted YFP+ cells contained the recombined YFP allele (Fig-
ure 3H), expressed transcripts for YFP, Pdx1, and E-cad
(Figure 3I), and carried the Gly/Asp mutation at codon 12 of
the Kras cDNA (Figures 3J and 3K). Thus, cells derived from
the pancreatic epithelium are present in the circulation of mice
with no evidence of carcinoma.
These data raised the possibility that CPCs from PanIN mice
might seed distant organs. To assess this possibility, we first
examinedPDACmice as a positive control. Bright-field stereomi-
croscopy permitted detection of peritoneal, liver, or lung metas-
tases in 8/20 animals; use of the YFP lineage label enhanced
detection, revealing micrometastases in 16/20 PDAC mice (Fig-
ure 3L). Next, we analyzed 8- to 10-week-old PKCY PanIN
mice. Although no animals hadmacro- or micrometastases, liver
seeding by YFP+ cells was detected in 4/11 PanIN mice (Figures
3M and 3N); most were single cells located near blood vessels
and expressed neither Zeb1 nor E-cad (Figures 3M and 3N). By
contrast, 0/10 livers from lineage-labeled control CY mice
harbored YFP+ cells when examined by the same technique.
Characterization of CPCs
The number of YFP+ CPCs from PDAC mice depended on the
location of blood collection, with a roughly 3-fold increase in
abundance in the right side of the heart compared to the left
side (Figure 4A). Only 2/9 PDAC mice had evidence of lung
metastases, suggesting that the vast majority of CPCs do not
survive passage through the pulmonary circulation. To deter-
mine whether cells in the circulation exhibited an epithelial,
mesenchymal, or mixed phenotype, we stained CPCs with
a variety of markers in a flow cytometric assay. The epithelial
markers E-cad, CK19, and EpCAM were detected in fewer
than 20% of PanIN CPCs and fewer than 40% of PDAC CPCs
(Figure 4B). With the exception of Fsp1—which was detected
in only 1.1% of all PanIN CPCs compared to 45.2% in PDAC
CPCs (p < 0.01)—there were no statistically significant differ-
ences in cell-surface phenotype between CPCs from the twogroups (Figure 4B). Coimmunofluorescence for Zeb1 and
EpCAM revealed that approximately 40% of PDAC CPCs were
Zeb1+, 27% were EpCAM+, and 18% were double positive
(Figure S4), suggesting that most CPCs do not exhibit a ‘‘mixed’’
epithelial-mesenchymal phenotype. These data indicate that
CPCs from PDAC and PanIN animals are phenotypically similar
and that a large fraction maintains a mesenchymal phenotype
in the circulation.
CPCs Exhibit Features of Cancer Stem Cells
Cancer stem cells are functionally defined as cells that have
enhanced tumor-initiating capacity upon transplantation into
a permissive host. In human pancreatic tumors, this activity
may be contained within a CD24+CD44+ population of cells,
among others (Hermann et al., 2007; Jimeno et al., 2009; Li
et al., 2007). Because EMT in primary cells has been associated
with the acquisition of stem cell-like characteristics (Mani et al.,
2008), we hypothesized that CPCs might also exhibit features
of cancer stem cells. We compared the relative abundance of
CD24+CD44+ cells in pancreata and CPCs from PanIN and
PDAC mice. By fluorescence-activated cell sorting (FACS) anal-
ysis, 0.11% ± 0.32% and 0.30% ± 0.13% of sorted YFP+ cells
from PanIN and PDAC pancreata, respectively, expressed
both CD24 and CD44 (Figure 4C). By contrast, 23.1% ± 12.9%
and 46.4% ± 14.7% of sorted YFP+ CPCs from PanIN and
PDAC samples were found to be CD24+CD44+, representing
a greater than 100-fold enrichment when compared to the
source pancreas (Figure 4D).
We next assessed the survival and self-renewal properties of
CPCs directly by employing an in vitro pancreatosphere assay,
in which single YFP+ cells were cultured in attachment-free
conditions (Rovira et al., 2010). In both PanIN and PDAC mice,
YFP+ CPCs had significantly greater rates of clonal survival
and growth compared to YFP+ pancreas cells from the same
animal (Figures 4E and 4F; p < 0.05). Taken together, these
data suggest that during tumor evolution in vivo, bloodstream
entry is associated with enrichment of cells that have phenotypic
and functional features associated with pancreatic cancer stem
cells.
Cells that Have Undergone EMT Have
Tumor-Initiating Properties
Although previous work has suggested a link between EMT and
increased tumor aggressiveness, most studies have relied on
in vitro manipulation of cancer cell lines to induce EMT (Wein-
berg, 2008). Such treatments could have a direct effect on cell
behavior apart from their EMT-inducing activity, and thus a direct
demonstration of the role of EMT in tumor progression is lacking.
We used our lineage-labeling system to isolate cells that had
either lost or retained E-cadherin expression to determine
whether an EMT in vivo is associated with tumor-initiating
capacity (Figure 5A).
First, we transplanted 100,000 YFP+E-cad+ or YFP+E-cad
pancreatic cells from PDAC mice into the pancreata of NOD/
SCID animals (n = 5 for each group). After 3weeks, all transplants
gave rise to large tumors with local invasion and distant metas-
tasis regardless of E-cad status at the time of transplantation;
tumors were histologically similar, and YFP+ cells coexpressingCell 148, 349–361, January 20, 2012 ª2012 Elsevier Inc. 353
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Figure 3. Hematogenous Spread and Liver Seeding Precede Tumor Formation
(A and B) Images showing individual YFP+ cells (green) intermingled with stromal cells prior to tumor formation in a 10-week-old PKCY PanIN mouse (A).
Delaminated YFP+ cells have a spindle-shaped morphology and express Zeb1 (boxes i–iii); they are indistinguishable from surrounding Zeb1+YFP stromal cells
by H&E staining of an adjacent section (B).
(C and D) FACS analysis of blood samples from age-matched CY control (C) and PKCY PanIN mice (D). YFP fluorescence and a stain for the leukocyte marker
CD45 are depicted on the x and y axes of the FACS plot. YFP+CD45 cells were seen in the blood of PanIN (D) and PDAC (not shown) animals (boxed area
indicates representative gating and absolute number of YFP+ cells).
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either Zeb1 or E-cad were found at comparable proportions in
both groups (Figures 5B–5E). This result suggests that tumor-
derived E-cad+ and E-cad cells can each form tumors and
that there is significant plasticity between epithelial and mesen-
chymal states.
By contrast, we observed a dramatic effect of E-cad status
on tumor formation when cells from PanIN mice were trans-
planted: 4/6 animals transplanted with 100,000 YFP+E-cad
cells formed tumors after 2 months, whereas 0/6 animals
transplanted with 100,000 YFP+E-cad+ cells formed tumors
over the same time period (Figures 5F–5I). Tumors derived
from E-cad PanIN cells were heterogeneous with respect to
E-cad and Zeb1 expression (Figures 5H and 5I). By compar-
ison, E-cad+ transplanted animals had few detectable YFP+
cells at the 2 month time point, and almost all of the YFP+ cells
detected were Zeb1 (Figure 5F). Mice transplanted with
E-cad+ PanIN cells eventually developed tumors (with
a mean latency of 4 months after transplantation) that were
indistinguishable from the PDAC-derived tumors. Thus, func-
tional analysis of tumor-initiating capacity revealed that
E-cad cells that have undergone EMT have a marked advan-
tage at the PanIN stage.
Inflammation Promotes EMT, Invasiveness,
and Dissemination
The emergence of PanIN lesions is associated with the appear-
ance of an inflammatory stroma characterized by activated fibro-
blasts andmyeloid-derived cells (Aguirre et al., 2003; Clark et al.,
2007). Inflammation is commonly correlated with tumor initiation
and progression (Coussens and Werb, 2002; Grivennikov et al.,
2010) and accelerates pancreatic carcinogenesis in adult Kras
mutant mice (Guerra et al., 2007, 2011). Our observation that
ADMIs have a high prevalence of EMT (Figure 3) led us to hypoth-
esize that inflammation contributes to EMT and dissemination at
the PanIN stage.
To address this possibility, we induced acute pancreatitis with
cerulein, a cholecystokinin analog that induces acinar cell death
(Siveke et al., 2008). Initially, KCY mice were analyzed to deter-
mine whether expression of oncogenic Kras alone facilitated
EMT and dissemination in response to acute pancreatitis. At
2 months of age, KCY mice had few PanIN lesions or inflamma-
tion at baseline; maximum PanIN grade found at this stage was
PanIN 1 (Figure 6B). As expected, cerulein treatment resulted in
the formation of ADMIs and accelerated PanIN formation
(compare Figures 6B and 6E; Figures S5A–S5D). Surprisingly,
cerulein treatment also resulted in a marked elevation in circu-(E) Quantification of circulating YFP+ pancreatic cells (CPCs). Mean CPC numbers
and 97.3 ± 48.9 (PDAC, n = 18) (p < 0.001).
(F and G) Phase-fluorescent images showing epifluorescence of a sorted YFP+ c
(H) Genomic PCR showing the presence of the recombined YFP allele in YFP+ c
included as a positive control.
(I) Expression of transcripts encoding YFP, Pdx1, and E-cad, comparing sorted Y
(J and K) Sanger sequencing after PCR amplification of cDNA showing that YFP
highlighted).
(L–N) CPCs from 8- to 10-week-old PKCY animals seed the liver. (L) Micrometast
CPCs seed the liver at the PanIN stage (‘‘PanIN Liver’’); vascular lumens are out
Scale bar, 40 mm for (A and (B); 5 mm for (L)–(N). See also Figure S3.lating cells, such that CPCs in 8-week-old cerulein-treated
KCY mice were almost as abundant as CPCs in vehicle-treated
PKCY mice of the same age (Figure 6G). Stated otherwise, cer-
ulein pancreatitis had nearly the same effect on CPC number as
the addition of a single floxed p53 allele. Similar changes were
observed in PKCY PanIN and PDAC mice treated with cerulein
(Figures 6C, 6F, S5E, and S5F), as well as control CY animals
treatedwith cerulein (Figures 6A and 6D), resulting in a significant
increase in CPC number across all groups following cerulein
treatment (p = 0.014 by two-way ANOVA; Figure 6G). CPCs
from cerulein-treated KCY mice exhibited a nearly 100-fold
enrichment of CD24+CD44+ cells compared to the source
pancreas, as had been observed for PanIN CPCs, although
this did not result in an increase in clonogenic growth for
KCY-derived CPCs in the pancreatosphere assay (Figures S4B
and S4C).
To confirm that inflammation promotes EMT and blood-
stream entry, we employed a second paradigm of pancreatitis
and performed pancreatic duct ligation (PDL) on 8- to
10-week-old PKCY PanIN mice. One week after PDL, the
portion of the pancreas distal to the ligation was enlarged
and nodular compared to the proximal portion from the
same mouse or sham-treated PanIN mice (Figures S6A
and S6D). This resulted in inflammation, more advanced
PanINs, and a loss of epithelial markers (Figures S6B, S6C,
S6E, and S6F), as well as an increase in CPCs (Figure S6G;
p = 0.042, n = 7). Thus, both chemical and surgical methods
for inducing pancreatitis result in an increase in EMT and
CPC number.
Finally, we sought to determine whether inflammation is
necessary for EMT and bloodstream entry. We treated
10-week-old PKCY mice with dexamethasone (Dex), a potent
anti-inflammatory drug that has no effect on pancreatic histology
in control animals (Figures 6H and 6K). As expected, vehicle-
treated mice at this age had PanIN lesions with an inflammatory
stroma and evidence of EMT but no tumors (Figures 6I and 6J).
Daily treatment with Dex (10 mg/kg for 7 days) resulted in
a marked reduction in inflammation (Figures 6L and 6M; n = 6
each group). Remarkably, PanINs and ADMIs were almost
undetectable in these pancreata (Figures 6K–6M), and this
change in histology was associated with a significant drop in
CPC number compared to vehicle-treated controls (Figure 6N).
Importantly, neither cerulein nor Dex treatment of PanIN-derived
epithelial cells in vitro had any effect on morphology, prolifera-
tion, or expression of epithelial or mesenchymal markers
(Figures S6H–S6N).(per ml blood) were 3.65 ± 3.76 (CY control, n = 13), 32.8 ± 26.2 (PanIN, n = 17),
ell.
ells but not YFP cells. Pancreatic DNA containing the recombined allele was
FP+ and YFP cells and measured by qPCR (±SD).
+ CPCs express a mutant Kras allele that harbors an altered codon 12 (G/A,
asis in a liver from a tumor-bearing mouse (‘‘PDAC Liver’’). (M and N) Individual
lined.
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Figure 4. CPC Characterization
(A) Quantification of CPCs after sampling from the left atrium or ventricle (‘‘Left’’) or right atrium or ventricle (‘‘Right’’) of the same animal (n = 3).
(B) Quantification of FACS staining for epithelial and mesenchymal markers in CPCs obtained from PanIN or PDAC mice (n = 6–8 for each data point).
(C and D) Quantification of YFP+ cells from the pancreas (C) and circulation (D) in PKCY PanIN and PDAC mice that stained positive for the putative pancreatic
cancer stem cell markers CD24 and CD44.
(E and F) Quantification of survival (E) or clonal growth (F) of YFP+ cells obtained from lineage-labeled control (CY), PanIN, and PDACmice in ultra-low attachment
wells. Bar graphs show the number of wells (out of 96 wells seeded with a single cell) exhibiting any live YFP+ cells (E, inset) or evidence of clonal growth (F, inset)
after 7 days.
p values for paired two-tailed Student’s t tests are shown. Scale bars, 10 mm. See also Figure S4.DISCUSSION
Invasive Behavior Precedes Frank Tumorigenesis
Using in vivo lineage tracing, we found that EMT, migration of
epithelially derived cells into the stroma, bloodstream entry,
and seeding of the liver occur at a stage of pancreatic adenocar-
cinoma progression previously thought to be preinvasive based
on standard histological examination. The relevance of these
findings to patients is supported by our detection of delaminated356 Cell 148, 349–361, January 20, 2012 ª2012 Elsevier Inc.Pdx1+ cells adjacent to PanIN lesions in sections of human pan-
creata. Thus, our data support a model for pancreatic cancer
progression in which the seeding of distant organs occurs
before, and in parallel to, tumor formation at the primary site.
Such an interpretation is especially applicable to PDAC, as the
vast majority of patients with pancreatic cancer have metastatic
disease at the time of diagnosis. More than 75% of patients who
undergo surgical resection of small pancreatic tumors with clear
surgical margins and no evidence of metastasis die from
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Figure 5. Epithelial and Mesenchymal States Are Plastic
(A) Schematic of orthotopic transplantation experiments.
(B–E) Fluorescent images taken 3 weeks after transplantation of YFP+ cells from PDAC mice into NOD/SCID hosts. Tumors form in all mice regardless of E-cad
status (n = 5 for each condition). YFP+E-cad+ and YFP+E-cad cells are present in both conditions (C and E), as are YFP+Zeb1+ and YFP+Zeb1 cells (B and D).
(F–I) Fluorescent images taken 8 weeks after transplantation of YFP+ cells from PanIN mice into NOD/SCID hosts. After transplantation of YFP+E-cad+ cells, no
tumors are found (n = 6); the few transplanted YFP+ cells that remain are Zeb1 and E-cad+ (F and G). Transplantation of YFP+E-cad cells results in tumor
formation (H and I). Tumors contain both E-cad+ and E-cad cells (I) as well as Zeb1+ and Zeb1 cells (H), providing direct evidence for MET.metastatic disease within 5 years (Neoptolemos et al., 2004),
a finding that is consistent with early spread. Moreover, meta-
static PDAC has been documented in a cohort of patients who
underwent pancreatectomy for chronic pancreatitis and in
whom histologic analysis of the resected pancreas revealed
only PanIN lesions (Sakorafas and Sarr, 2003).
Recent genetic studies examining low-passage cell lines or
microdissected primary tumors and matched metastases have
concluded that metastasis is a late event in human PDAC
(Campbell et al., 2010; Yachida et al., 2010). In these studies,
a large proportion of mutations were shared among primary
andmetastatic lesions, leading to the conclusion that metastasis
constituted a terminal event in the disease process. However,mathematical modeling of such phylogenetic relationships relies
on assumptions about proliferation and mutation rates at stages
of metastatic progression (e.g., micrometastasis) that are not
measured easily. Indeed, the notion that colonization occurs
early in PDAC is supported by the observation that proliferation
is significantly lower in metastatic lesions (Okimura et al., 2009)
compared to the primary tumor (Yachida et al., 2010), and yet
their sizes at the time of diagnosis are similar.
Our in vivo studies do not provide direct evidence that CPCs
from PanIN mice (and the corresponding liver-seeding cells)
ultimately give rise to metastases. Nevertheless, several lines
of evidence indicate that at least some of these cells may
be capable of doing so. First, CPCs found in the blood ofCell 148, 349–361, January 20, 2012 ª2012 Elsevier Inc. 357
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Figure 6. Inflammation Augments EMT and Dissemination
(A–F) Fluorescent images of 8-week-old control Pdx1-Cre; Rosa YFP (CY; A and D), KrasG12D; Pdx1-Cre; Rosa YFP (KCY; B and E), and PanIN (C and F) pancreata
3 days after injectionwith vehicle (A–C) or cerulein (D–F) to induce acute pancreatitis (n = 3 for each condition). YFP+Zeb1+ cells present in PanINmice or observed
following cerulein treatment of CY and KCY mice are shown (C–F, insets).
(G) Quantification of CPC number after 3 days of treatment with vehicle or cerulein for micewith the indicated genotypes (n = 3 for each group; p < 0.05 comparing
the two groups of KCY mice by Student’s t test; p = 0.014 for the effect of cerulein versus control across all groups by two-way ANOVA).
(H–M) Images of 10-week-old control (H and K) and PanIN pancreata (I and J, L and M) after 7 days of treatment with vehicle (DMSO; H–J) or dexamethasone
(Dex; K–M) and analyzed 24 hr after the last injection. YFP+Zeb1+ cells are seen in vehicle-treated controls (J, inset) but not in Dex-treated animals (M, inset).
(N) Quantification of CPC number in vehicle- and Dex-treated PanIN mice (p = 0.029, n = 6 for each group).
See also Figure S6.PanIN-bearing mice exhibit increased survival and self-renewal
properties in vitro, suggesting that they may be able to persist
for long periods of time in a foreign environment such as the liver.
Second, most PanIN-derived CPCs exhibit a YFP+E-cad cell-
surface phenotype, which our transplantation experiments
showed was associated with enhanced tumor-initiating
capacity. Finally, a wealth of clinical and experimental data
from other systems is consistent with early spread (Weinberg,
2008). Additional experiments will be needed to prove that cells
that enter the circulation prior to the development of frank malig-
nancy have metastatic potential. Nevertheless, the finding by
routine histology that delaminating cells are indistinguishable
from surrounding stromal cells indicates that current histological
criteria to diagnose invasive PDACmay be inadequate. Our data
also suggest that the location of sampling within the peripheral
blood may influence the detection rate of circulating cells.358 Cell 148, 349–361, January 20, 2012 ª2012 Elsevier Inc.EMT, MET, and the Acquisition of Stem Cell
Characteristics
Lineage tracing enabled us to distinguish pancreatic cells that
had acquired mesenchymal characteristics from those that
retained an epithelial phenotype. The majority of labeled cells
that delaminated from the epithelium (i.e., locally invasive cells)
expressed Zeb1, indicating that they had undergone EMT. This
strong correlation between invasive behavior and the acquisition
of mesenchymal characteristics in vivo suggests that EMT is not
merely an epiphenomenon but rather represents a critical hurdle
that cells must clear to escape from their epithelial neighbors. At
present, the signals that initiate EMT in advanced PanINs and
ADMIs in vivo remain to be determined.
When PDAC cells were separated according to EMT status
(i.e., YFP+E-cad+ or YFP+E-cad) and transplanted orthotopi-
cally into the pancreas, the resultant tumors were similar with
respect to their epithelial and mesenchymal composition. This
result demonstrates that an epithelial or mesenchymal pheno-
type is not a stable property of a malignant cell and provides
direct evidence for a mesenchymal-to-epithelial transition
(MET) in vivo. We also noted that orthotopically transplanted
YFP+E-cad cells from 8- to 10-week-old PKCY PanIN mice
gave rise to tumors with a much shorter latency than the same
number of YFP+E-cad+ cells. One interpretation of this result is
that cells that have undergone EMT at the PanIN stage are
more tumorigenic; alternatively, the YFP+E-cad population
may be enriched for a subset of cells with greater or more rapid
tumor-initiating properties. In either case, our findings highlight
the striking degree of plasticity that exists between epithelial
and mesenchymal states during tumor progression in vivo.
In the PKCY model, cells with a CD24+CD44+ phenotype—
a population possessing tumor-initiating properties by xenograft
assay (Li et al., 2007)—were significantly enriched in the circula-
tion compared to the pancreas. Accordingly, circulating cells
exhibited increased survival and self-renewal in low-attachment
conditions. Thus, our findings provide in vivo support for the
notion that EMT is associated with the initiation of a stem cell
program (Mani et al., 2008) and indicate that acquisition of
a CD24+CD44+ phenotype facilitates entry into the circulation
and/or survival within the bloodstream.
The development of technologies to identify circulating tumor
cells (CTCs) from patients represents an enormous advance in
metastasis research (Pantel et al., 2008). CTC number correlates
with clinical outcome and response to chemotherapeutics in
many cancers (Cristofanilli et al., 2004), and isolated dissemi-
nated cells can be interrogated for molecular changes that are
associated with an increased risk of death (Stoecklein et al.,
2008). CTC biology thus has both clinical utility and the potential
to advance our understanding of the metastatic cascade.
However, standard techniques for isolating CTCs rely heavily
upon the use of epithelial markers, particularly EpCAM, for
detection (Pantel et al., 2008). The presence of EpCAM-negative
YFP+ CPCs in our studies raises several possibilities: (1) stan-
dard methods that employ epithelial epitopes may not capture
all CTCs; (2) cells may enter the circulation after undergoing an
‘‘incomplete’’ EMT, in which residual expression of EpCAM is
maintained but not detected by flow cytometry; or (3) CTCs
may enter the bloodstream with a mesenchymal phenotype
and subsequently ‘‘revert’’ to an epithelial phenotype through
a process of MET.
Inflammation Promotes EMT and Dissemination
Inflammation has a well-established role in promoting tumor
progression (Grivennikov et al., 2010). Using two models of
pancreatitis, we have demonstrated that inflammation induces
EMT in CY and KCY animals and results in an increase in CPC
number across all genotypes tested. Although mice bearing
a single mutant Kras allele seemed to have the greatest increase
in CPC number following cerulein treatment, even nonmutant
pancreatic cells underwent EMT and entered the circulation in
the setting of inflammation. This latter observation is quite
surprising, as hematogenous spread has not been thought to
occur in adult animals in the absence of a tumor. Phenotypically
normal cells injected into the bloodstream can seed distantorgans and persist for long periods of time until stimulated to
grow (Podsypanina et al., 2008), and in both mice and humans,
chronic pancreatic inflammation is strongly associated with
pancreatic cancer (Grover and Syngal, 2010; Guerra et al.,
2007). Our study suggests that inflammation may promote
cancer progression through two independent mechanisms: by
facilitating changes in the microenvironment at the primary site
of neoplasia and by facilitating invasion and dissemination by
increasing cellular access to the circulation.
There is likely to be heterogeneity among pancreatic epithelial
cells at the PanIN stage, and it is possible that bloodstream entry
prior to the development of a recognizable tumor is facilitated by
loss of the second allele of p53 in PKCY mice. However, the
increase of CPCs in KCY and CY mice (which bear no cancer-
promoting mutations) following experimental pancreatitis
suggests that loss of this tumor suppressor gene is not required
for bloodstream entry. Interestingly, although pancreatitis
augmented CPC number in KCY animals, these cells did not
have the same clonal growth properties exhibited by PKCY
CPCs (compare Figure S4C with Figure 4F), supporting the
notion that p53 loss enhances the survival and/or self-renewal
of circulating cells.
Finally, we have demonstrated that the inflammatory stroma is
necessary for EMT and dissemination. Treatment of 10-week-
old PKCY mice with dexamethasone for 1 week resulted in an
almost complete elimination of PanIN lesions in the pancreas
and loss of YFP+ cells from the blood, underscoring a critical
requirement for the inflammatory stroma in the maintenance of
premalignant PanIN lesions. Similar regression of murine PanIN
disease was also seen after treatment with the cyclooxygenase-
inhibitor sulindac (Guerra et al., 2011). Our findings have implica-
tions for the management of individuals at high risk for pancre-
atic cancer, including patients with hereditary pancreatitis or
kindreds with inherited pancreatic cancer. If dissemination and
seeding of pancreatic epithelial cells precede the detection of
a tumor in humans, as they do in the mouse model, a window
of opportunity may exist for prophylactic therapy in high-risk
patients. Indeed, anti-inflammatory drugs have proven moder-
ately successful at reducing mortality due to several cancers,
including PDAC (Rothwell et al., 2011).EXPERIMENTAL PROCEDURES
Mouse Strains and Experimental Treatment
The behavior of mutant strains bearing various allele combinations of Pdx1-
Cre, KrasG12D, p16/p19fl, and p53fl has been described previously (Aguirre
et al., 2003; Bardeesy et al., 2006; Hingorani et al., 2003). To perform lineage
tracing, we introduced a RosaYFP reporter allele into these mutant back-
grounds to generate a panel of compound mutant strains: Pdx1-Cre; RosaYFP
(‘‘CY’’), Pdx1-Cre; KrasG12D; RosaYFP (‘‘KCY’’), Pdx1-Cre; KrasG12D; p16/
p19fl/+; RosaYFP (‘‘IKCY’’), and Pdx1-Cre; KrasG12D; p53fl/+; RosaYFP
(‘‘PKCY’’). All experiments involving the KCY model employed mice between
8 and 10 weeks of age. For studies involving mice harboring only PanIN
lesions by histologic analysis (‘‘PanIN’’ mice), PKCY animals were sacrificed
at 8–10 weeks of age based on prior observations regarding tumor progres-
sion (Bardeesy et al., 2006); no PKCY mice (out of 18 examined) had evidence
of carcinoma at this time point (see Extended Experimental Procedures for
details of histological analysis by a pancreatic pathologist [A.M.]).
For PDAC mice, animals were examined three times per week for evidence
of morbidity and sacrificed when they exhibited limited physical activity,Cell 148, 349–361, January 20, 2012 ª2012 Elsevier Inc. 359
depressed response to toe pinch, dehydration, and/or abdominal enlargement
from ascites. More than 90% of IKCY and PKCY mice were 34–38 weeks of
age or 16–20 weeks of age, respectively, at the time of sacrifice.
Experimental pancreatitis was elicited with cerulein as described (Siveke
et al., 2008), and specimens were obtained after 3 days of treatment. Three
to four CY, KCY, PanIN PKCY, and PDAC PKCY were used for cerulein and
vehicle (PBS) treated cohorts. Orthotopic transplantations were performed
on NOD/SCID mice by injecting 1 3 105 sorted pancreas cells as previously
described (Mohammad et al., 1998). PKCY PanIN mice aged 10 weeks were
treated with seven daily injections of dexamethasone or vehicle (DMSO) as
described (Stairs et al., 2011) and analyzed 24 hr later.
Cell Staining
For experiments involving flow cytometry and sorting of pancreatic cells, at
least 25% of the tissue was saved for histologic analysis and was processed
and stained as described in the Extended Experimental Procedures.
Pancreatosphere Assay
YFP+ blood or pancreatic cells from the samemousewere sorted into ultra-low
attachment 96-well plates (Corning) at 1 cell per well, confirmed by micros-
copy. Cells were grown as previously described (Rovira et al., 2010) and as-
sayed at 5 days for clonal growth of fluorescent cells (defined as clusters of
cells >3 cell widths in diameter) or presence of live YFP+ cells (singlets or
doublets). Three to four mice were analyzed for each category.
Additional information can be found in the Extended Experimental
Procedures.SUPPLEMENTAL INFORMATION
Supplemental Information includes Extended Experimental Procedures, six
figures, and two tables and can be found with this article online at doi:10.
1016/j.cell.2011.11.025.
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